MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Baxter International EBITDA 2011-2026 | BAX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Baxter International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 673 M | 1.01 B | 1.69 B | -1.77 B | 2.22 B | 2.44 B | 1.66 B | 2.43 B | 2.02 B | 1.52 B | 1.21 B | 3.71 B | 3.49 B | 3.53 B | 3.62 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.71 B | -1.77 B | 1.96 B |
Quarterly EBITDA Baxter International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 262 M | 297 M | 305 M | 250 M | 252 M | 386 M | 326 M | 140 M | 442 M | - | -2.71 B | 457 M | 543 M | - | 1.16 B | 491 M | 607 M | - | 1.08 B | 732 M | 608 M | - | 1.08 B | 735 M | 575 M | 391 M | 968 M | 764 M | 624 M | - | 862 M | 725 M | 547 M | - | 785 M | 463 M | 377 M | - | 685 M | 464 M | 279 M | - | 809 M | 489 M | 236 M | - | 573 M | 366 M | 183 M | - | 534 M | 355 M | 175 M | - | 503 M | 327 M | 158 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.16 B | -2.71 B | 449 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Harvard Bioscience
HBIO
|
-46.8 M | $ 5.13 | - | $ 228 M |  USA |
 |
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | USA |
 |
Intuitive Surgical
ISRG
|
3.55 B | $ 469.98 | -0.41 % | $ 168 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | USA |
 |
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | USA |
 |
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | USA |
 |
Repro Med Systems
KRMD
|
-2.16 M | $ 4.41 | 0.23 % | $ 204 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-11.8 M | $ 10.98 | 4.57 % | $ 26.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
78.3 M | $ 111.08 | 0.99 % | $ 2.51 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | USA |
 |
Masimo Corporation
MASI
|
-164 M | $ 178.09 | -0.34 % | $ 9.49 B | USA |
 |
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | USA |
 |
Milestone Scientific
MLSS
|
-6.72 M | $ 0.3 | 2.11 % | $ 23.9 M | USA |
 |
Merit Medical Systems
MMSI
|
308 M | $ 68.11 | 0.83 % | $ 4.03 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | USA |
 |
Haemonetics Corporation
HAE
|
337 M | $ 55.93 | -1.29 % | $ 2.81 B | USA |
 |
Nephros
NEPH
|
-1.38 M | $ 3.02 | -0.98 % | $ 31.4 M | USA |
 |
Envista Holdings Corporation
NVST
|
332 M | $ 26.14 | 0.42 % | $ 4.39 B | USA |
 |
Pro-Dex
PDEX
|
11.9 M | $ 48.61 | -2.76 % | $ 160 M | USA |
 |
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 31.1 M | USA |
 |
OraSure Technologies
OSUR
|
-61.8 M | $ 3.14 | 2.61 % | $ 231 M | USA |
 |
Pulse Biosciences
PLSE
|
-76.5 M | $ 22.02 | 3.43 % | $ 1.48 B | USA |
 |
AngioDynamics
ANGO
|
-14.2 M | $ 11.22 | 5.55 % | $ 458 M | USA |
 |
AtriCure
ATRC
|
2.64 M | $ 29.53 | -0.27 % | $ 1.41 B | USA |
 |
InfuSystem Holdings
INFU
|
15 M | $ 9.79 | 1.03 % | $ 202 M | USA |
 |
Repligen Corporation
RGEN
|
116 M | $ 114.32 | -1.7 % | $ 6.37 M | USA |
 |
iRhythm Technologies
IRTC
|
-36.7 M | $ 121.79 | 2.61 % | $ 3.9 B | USA |
 |
Retractable Technologies
RVP
|
-13.5 M | $ 0.72 | 0.01 % | $ 21.6 M | USA |
 |
BioLife Solutions
BLFS
|
-1.97 M | $ 19.86 | 0.81 % | $ 915 M | USA |
 |
ResMed
RMD
|
1.16 B | $ 226.31 | -0.82 % | $ 33.1 B | USA |
 |
STERIS plc
STE
|
1.34 B | $ 223.38 | 0.74 % | $ 22 B | USA |
 |
electroCore
ECOR
|
-12.7 M | $ 6.69 | 8.43 % | $ 56.8 K | USA |
 |
Stereotaxis
STXS
|
-21.5 M | $ 1.86 | 3.33 % | $ 169 M | USA |
 |
Teleflex Incorporated
TFX
|
192 M | $ 108.18 | 1.52 % | $ 4.83 B | USA |
 |
STAAR Surgical Company
STAA
|
-83.4 M | $ 19.19 | 1.16 % | $ 951 M | USA |
 |
Glaukos Corporation
GKOS
|
-95 M | $ 109.6 | 4.15 % | $ 5.31 B | USA |
 |
Utah Medical Products
UTMD
|
17.4 M | $ 63.71 | -0.14 % | $ 231 M | USA |
 |
West Pharmaceutical Services
WST
|
756 M | $ 247.02 | 0.71 % | $ 17.9 B | USA |
 |
The Cooper Companies
COO
|
1.06 B | $ 71.45 | 1.36 % | $ 14.2 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-70 M | $ 11.68 | 1.88 % | $ 2.33 B | USA |
 |
Becton, Dickinson and Company
BDX
|
5.04 B | $ 158.27 | 1.51 % | $ 45.5 B | USA |
 |
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | USA |
 |
ICU Medical
ICUI
|
244 M | $ 131.38 | 1.53 % | $ 3.24 B | USA |
 |
Microbot Medical
MBOT
|
-9.75 M | $ 2.53 | 1.2 % | $ 25.8 M |  Israel |
 |
Alcon
ALC
|
580 M | $ 75.26 | 1.37 % | $ 40.4 B |  Schweiz |